Drugs · Entity Annotation Prototype (beta)

3articles mentioning drugs

5drug mentions

1distinct drugs extracted

0%of mentions human-reviewed

Active filtersEntity: gemtuzumab ozogamicin ×

gemtuzumab ozogamicin

This drug is selected. Its supporting articles are shown below.

gemtuzumab ozogamicin3

Articles mentioning gemtuzumab ozogamicin

3 articles · page 1 of 1

Impact of immunotherapy and small molecule cancer therapy on fertility: a narrative review of current evidence, mechanisms and future directions

bmjonc · full text · 2026-01-28 · 2 matching annotations

94.4%

pembrolizumab bortezomib crizotinib pembrolizumab35 sunitinib dasatinib

…umab) are often used in ovarian and cervical cancers. ICIs (eg, pembrolizumab) are effective in mismatch repair-deficient endometrial cancer …

689 The mTORC1/2 dual inhibitor AZD2014 enhances inotuzumab ozogamicin-induced apoptosis in B-cell non-hodgkin lymphoma cells via lysosomal function activation

jitc · abstract · 2025-11-04 · 2 matching annotations

98.9%

gemtuzumab ozogamicin Inotuzumab ozogamicin AZD2014 gemtuzumab ozogamicin-induced IO Kobe University B-cell non-Hodgkin lymphoma B-cell acute lymphoblastic leukemia B-cell NHL diffuse large B-cell lymphoma (DLBCL)

…t al. An mTORC1/2 kinase inhibitor enhances the cytotoxicity of gemtuzumab ozogamicin by activation of lysosomal function. Leuk Res. 2018 Nov;74:68–7…

4CPS-249 Defibrotide prophylaxis in high-risk paediatric patients undergoing haematopoietic stem cell transplantation: real-world cohort

ejhpharm · abstract · 2026-03-18 · 1 matching annotations

93.3%

defibrotide Gemtuzumab Inotuzumab gemtuzumab ozogamicin adrenoleukodystrophy neuroblastoma SOS AML Sinusoidal obstruction syndrome (SOS)

…ary paediatric hospital, who met SOS risk criteria and received defibrotide prophylaxis.Material and Methods Retrospective cohort of paedia…